Pyridine → HCID 136352256, 화합물

HRID 1047546노트

반응식

HRID 1047546 반응식
[CH:1]1([N:4]=[C:5]=[O:6])[CH2:3][CH2:2]1.[NH:7]1[C:11]2[CH:12]=[CH:13][CH:14]=[CH:15][C:10]=2[N:9]=[C:8]1[C:16]1[C:24]2[C:19](=[CH:20][CH:21]=[C:22]([NH2:25])[CH:23]=2)[N:18]([CH:26]2[CH2:31][CH2:30][CH2:29][CH2:28][O:27]2)[N:17]=1.N1C=CC=CC=1>C(Cl)Cl>[NH:9]1[C:10]2[CH:15]=[CH:14][CH:13]=[CH:12][C:11]=2[N:7]=[C:8]1[C:16]1[C:24]2[C:19](=[CH:20][CH:21]=[C:22]([NH:25][C:5]([NH:4][CH:1]3[CH2:3][CH2:2]3)=[O:6])[CH:23]=2)[N:18]([CH:26]2[CH2:31][CH2:30][CH2:29][CH2:28][O:27]2)[N:17]=1

참가 물질

5

반응물 3

HCID 1049PyridineHCID 637659IsocyanatocyclopropaneHCID 1363522453-(1H-benzo[d]imidazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine

생성물 1

HCID 136352256HCID 136352256, 화합물수율 53.4%

시약·촉매·용매 1

HCID 6344Dichloromethane용매

실험 절차

Cyclopropylisocyanate (4 g, 0.048 mmol) was added to a solution of 3-(1H-benzo[d]imidazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (15 mg, 0.045 mmol) and pyridine (0.01 mL, 0.126 mmol) in CH2Cl2 (5 mL). The mixture was stirred for 24 h, and then the solvent was removed in vacuo. Purification by flash chromatography (2% CH3OH/CH2Cl2) afforded the title compound (10 mg) as a solid. 1H NMR (400 MHz, CDCl3): δ 8.22 (s, 1H), 7.93 (d, 1H, J=8.8 Hz), 7.83 (m, 1H), 7.49 (d, 1H, J=8.8 Hz), 7.27-7.24 (m, 2H), 7.17 (s, 1H), 5.71 (dd, 1H, J=2.4 and 9.2 Hz), 4.04 (m, 1H), 3785 (m, 1H), 2.59 (m, 2H), 2.17-2.07 (m, 2H), 1.74 (m, 5H), 0.84 (q, 2H, J=5.2 Hz).

후처리

  1. customthe solvent was removed in vacuo
  2. customPurification by flash chromatography (2% CH3OH/CH2Cl2)

출처 및 근거

ORD 기록
ord-223a9deade0341fcb829a5b1386c58c3
출처 데이터셋
uspto-grants-2013_10
특허 번호
US08569511B2

반응 노트

불러오는 중…